Who makes Alluzience?

Alluzience is developed by Galderma R&D.

What development phase is Alluzience in?

Alluzience is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Alluzience

Galderma R&D · FDA-approved active Biologic Quality 0/100

Alluzience, marketed by Galderma R&D, is a dermatological product with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging Galderma's strong brand and distribution network. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Alluzience
Sponsor	Galderma R&D
Modality	Biologic
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Comparing Treatment With Alluzience vs Reconstituted Toxin (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Alluzience CI brief — competitive landscape report
Alluzience updates RSS · CI watch RSS
Galderma R&D portfolio CI